当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2016年第2期
编号:12758598
BET家族基因表达与恶性肿瘤患者总生存期及临床病理特征的关系(4)
http://www.100md.com 2016年1月15日 中国医药导报 2016年第2期
     [16] Yan Y,Yang FQ,Zhang HM,et al. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder [J]. Int J ClinExpPathol,2014,7(7):4231-4238.

    [17] Gyorffy B,Lanczky A,Eklund AC,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients [J]. Breast Cancer Res Treatment,2010, 123(3):725-731.

    [18] Gyorffy B,Lanczky A,Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients [J]. Endocrine-Related Cancer,2012,19(2):197-208.

    [19] Gyorffy B,Surowiak P,Budczies J,et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer [J].PLoS One,2013,8(12):e82241.

    [20] Stewart HJ,Horne GA,Bastow S,et al. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is im-plicated in apoptosis by the bromodomain inhibitor JQ1 [J]. Cancer Med,2013,2(6):826-835.

    (收稿日期:2015-10-08 本文编辑:苏 畅), 百拇医药(王婧文 唐菲 邓磊 纳飞飞 薛建新 卢铀)
上一页1 2 3 4